Omega-3:
What the evidence
actually shows

The 2021 meta-analysis by Bhatt et al. covering 149,051 participants across 38 RCTs is the most comprehensive current synthesis of the omega-3 and cardiovascular outcomes literature. It found significant reductions in cardiovascular mortality, non-fatal MI, coronary heart disease events, and revascularisation rates. The effect was present but the magnitude of benefit varied considerably by formulation, dose, and whether EPA was used alone or combined with DHA. EPA monotherapy trials consistently showed larger relative risk reductions than EPA+DHA combined trials. This has important practical implications for supplement selection that most general guidance ignores.

EPA and DHA are often bundled together as "omega-3" in both research and supplement marketing, but they are chemically distinct compounds with different biological actions. EPA has more potent anti-inflammatory and triglyceride-lowering effects. DHA is the predominant structural fatty acid in brain and retinal tissue. The leading hypothesis for why EPA monotherapy outperforms combined EPA+DHA products in cardiovascular trials is that DHA may partially offset EPA's anti-inflammatory and membrane-stabilising effects through competing mechanisms. The REDUCE-IT trial, 8,179 patients, 4.9 years follow-up, used high-dose purified EPA (icosapent ethyl, 4g/day) and showed a 25% reduction in major adverse cardiovascular events. No comparable high-dose DHA-only trial exists with equivalent results.

Omega-3 fatty acids, particularly EPA, act as precursors for specialised pro-resolving mediators (SPMs), resolvins and protectins, that actively resolve inflammation rather than just suppressing it. This is mechanistically distinct from non-steroidal anti-inflammatory drugs, which block inflammatory signalling. At the cellular level, EPA competes with arachidonic acid for the same enzymatic pathways, reducing production of pro-inflammatory eicosanoids and shifting the balance towards anti-inflammatory metabolites. This mechanism has implications beyond cardiovascular risk: it underpins much of the research interest in omega-3 for joint health, inflammatory conditions, and recovery from training. The anti-inflammatory effects are dose-dependent and require consistent supplementation, single doses produce limited benefit.

Standard fish oil capsules sold in UK pharmacies and supermarkets typically contain 180mg EPA and 120mg DHA per capsule, with a recommended dose of 1–2 capsules daily. This provides 180–360mg of combined EPA+DHA, a fraction of the doses used in the most clinically meaningful trials. The REDUCE-IT trial used 4g/day of EPA. Most general health trials use 1–2g/day of combined EPA+DHA. The 2021 Bernasconi meta-analysis in Mayo Clinic Proceedings found the cardiovascular protective effect was dose-dependent, with larger reductions in MI risk at higher doses. If you are taking one standard capsule daily and expecting meaningful cardiovascular benefit, the dose is unlikely to be sufficient.

The most consistently demonstrated metabolic effect of omega-3 supplementation is triglyceride reduction. At doses of 2–4g/day, EPA and DHA reliably reduce fasting triglycerides by 15–30% in people with elevated levels. This is one of the most robust effects in the supplement literature and is reflected in prescription-grade omega-3 products being licensed specifically for hypertriglyceridaemia. The mechanism involves reduced hepatic VLDL production and enhanced clearance of triglyceride-rich lipoproteins. For individuals with fasting triglycerides above 1.7 mmol/L, a common finding in metabolically unhealthy adults, adequate omega-3 intake is one of the most straightforward dietary interventions available.

Approximately 60% of the brain's dry weight is fat, of which DHA is the most abundant polyunsaturated component. Adequate DHA intake is associated with preserved cognitive function in ageing, reduced risk of cognitive decline, and improved neurological development in infants. the latter being the most established evidence base. The adult cognitive health data is more mixed: observational studies consistently show associations between higher omega-3 status and lower dementia risk, but RCT data on supplementation in healthy adults with adequate baseline omega-3 status shows limited additional benefit. The implication is that the benefit accrues from having adequate omega-3 status, not from supplementing on top of adequate levels. If your diet is low in oily fish, supplementation is appropriate; if you eat oily fish regularly, the incremental cognitive benefit of additional supplementation is uncertain.

Standard supplemental doses of EPA+DHA (1–3g/day) have a well-established safety profile in healthy adults. The primary safety concern with high-dose EPA is a dose-dependent increase in atrial fibrillation (AF) risk, which was observed in the REDUCE-IT trial and confirmed in subsequent meta-analyses. The absolute risk is small, but clinically relevant for individuals with pre-existing AF risk factors. High-dose omega-3 also mildly extends bleeding time, a consideration for people on anticoagulants or scheduled for surgery. At standard supplemental doses (1–2g/day), neither concern is clinically significant in healthy adults without pre-existing cardiovascular conditions.

The benefits observed in observational studies correlating omega-3 intake with health outcomes were largely driven by dietary fish consumption, not supplementation. Oily fish provides not just EPA and DHA but also protein, selenium, iodine, and vitamin D, a nutritional package that supplementation does not replicate. If dietary intake is adequate (approximately 2–3 servings of oily fish per week, the added benefit of supplementation is modest at best for otherwise healthy individuals. Where supplementation is most clearly warranted: people who do not eat oily fish regularly, vegetarians and vegans (who should use algae-derived DHA/EPA rather than fish-derived), and individuals with elevated cardiovascular risk who benefit from higher doses than diet alone can provide.